Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA.
Keck School of Medicine of the University of Southern California, Los Angeles, CA.
J Arthroplasty. 2022 Aug;37(8S):S958-S963. doi: 10.1016/j.arth.2022.02.057. Epub 2022 Feb 18.
Advances in surgical technique and prosthesis design have expanded the non-neoplastic indications for proximal femoral replacement (PFR) to include fracture nonunion, periprosthetic fracture, and severe bone loss in the setting of revision total hip arthroplasty (THA). The purpose of this study is to assess outcomes of PFRs used for nononcologic indications.
A single-institution, retrospective, cohort survey study was conducted between August 2015-February 2020 of consecutive patients undergoing PFR for nononcologic indications in revision THA. Patient demographics, surgical variables, complications, and revision procedures were collected. Patient satisfaction and Oxford Hip scores were assessed via a telephone questionnaire. Implant survivorship was estimated using the Kaplan-Meier method.
In total, 24 patients (27 PFRs) were available for analysis with an average age of 69.3 ± 12.9 years (range: 37-90). The average number of operations prior to PFR implantation was 3.1 ± 2.1 (range: 0-7). At a mean follow-up of 2.4 years (range: 0.5-5.1), the mean Oxford Hip Score was 31.7 ± 10.2, and mean patient satisfaction was 4.9/5. Six patients (20.7%) experienced a postoperative complication, with dislocation occurring in three patients (10.3%). None of the patients with dual mobility articulations (n = 4) had dislocation. Three-year survivorship was 85.2% (95% CI 71.8%-98.6%) with all-cause reoperations as the endpoint and 100% (95% CI 100.0%-100.0%) with revision for aseptic loosening as the endpoint.
The current study demonstrates excellent short-term survivorship, satisfactory patient-reported outcomes, and high patient satisfaction following PFR for nononcologic indications during revision THA utilizing modern techniques. The most common mode of failure was dislocation requiring reoperation with revision to constrained acetabular components.
手术技术和假体设计的进步扩大了近端股骨置换术(PFR)的非肿瘤适应证,包括骨折不愈合、假体周围骨折和翻修全髋关节置换术(THA)时严重的骨丢失。本研究旨在评估用于非肿瘤适应证的 PFR 的结果。
对 2015 年 8 月至 2020 年 2 月期间在翻修 THA 中因非肿瘤适应证而行 PFR 的连续患者进行了单中心回顾性队列研究。收集了患者人口统计学、手术变量、并发症和翻修手术的资料。通过电话问卷调查评估患者满意度和牛津髋关节评分。使用 Kaplan-Meier 方法估计植入物存活率。
共 24 例患者(27 个 PFR)接受了分析,平均年龄为 69.3±12.9 岁(范围:37-90)。在植入 PFR 之前,平均手术次数为 3.1±2.1(范围:0-7)。在平均 2.4 年(范围:0.5-5.1)的随访中,平均牛津髋关节评分为 31.7±10.2,平均患者满意度为 4.9/5。6 例患者(20.7%)发生术后并发症,3 例(10.3%)发生脱位。4 例采用双动关节的患者中无一例发生脱位。以全因再手术为终点,3 年生存率为 85.2%(95%CI 71.8%-98.6%),以无菌性松动为终点,生存率为 100%(95%CI 100.0%-100.0%)。
本研究表明,在翻修 THA 中采用现代技术治疗非肿瘤适应证的 PFR 可获得极好的短期存活率、满意的患者报告结果和较高的患者满意度。最常见的失效模式是需要翻修为约束性髋臼组件的脱位再手术。